Table 4. Rates of Any Adverse Event and Medical Attention for Any Influenza Vaccine Stratified by Vaccine Type and According to Whether Influenza Vaccine Was Administered With a Concomitant Vaccine.
| Outcome | Respondents, No./Total (%) | ||||
|---|---|---|---|---|---|
| Overall | Only influenza vaccine | Concomitant vaccinea | |||
| Any | PPSV23 | Zoster | |||
| Any influenza vaccine | |||||
| Any adverse event | 3684/50 134 (7.4) | 2778/43 958 (6.3) | 906/6176 (14.7) | 761/4229 (18.0) | 112/1370 (8.2) |
| Medical attention | 141/49 493 (0.3) | 95/43 434 (0.2) | 46/6059 (0.8) | 40/4140 (1.0) | 6/1355 (0.5) |
| aIIV3 | |||||
| Any adverse event | 1796/28 003 (6.4) | 1340/24 762 (5.4) | 456/3241 (14.1) | 378/2178 (17.4) | 54/742 (7.3) |
| Medical attention | 80/27 665 (0.3) | 55/24 486 (0.2) | 25/3179 (0.8) | 23/2133 (1.1) | 1/732 (0.1) |
| HD-IIV3 | |||||
| Any adverse event | 1716/19 306 (8.9) | 1318/16 754 (7.9) | 398/2552 (15.6) | 341/1799 (19.0) | 50/565 (8.9) |
| Medical attention | 56/19 030 (0.3) | 38/16 525 (0.2) | 18/2505 (0.7) | 14/1760 (0.8) | 5/560 (0.9) |
Abbreviations: aIIV3, adjuvanted trivalent inactivated influenza vaccine; HD-IIV3, high-dose trivalent inactivated influenza vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
a
Participants may have received one or more concomitant vaccines. PPSV23 vaccine was the most commonly administered concomitant vaccine among those 65 years or older, administered to 68.5% of participants. Zoster vaccine was the second most commonly administered concomitant vaccine, administered to 22.2% of participants.